Key result
Moderate-intensity statins reduced LDL-C by ~45% at 3 months in Korean patients, suggesting lower doses may be highly effective in Asian populations.
Why the study?
Do low- and moderate-intensity statins provide sufficient LDL-C lowering efficacy in Korean patients compared to ACC/AHA guideline expectations?
Cohort (n=2,349)
No
Do low- and moderate-intensity statins provide sufficient LDL-C lowering efficacy in Korean patients compared to ACC/AHA guideline expectations?
Moderate-intensity statins produce greater LDL-C reductions in Korean patients than expected by ACC/AHA guidelines, suggesting lower doses may be sufficient for this population.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for lower statin doses in Asians; leaves open need for randomized confirmation before practice change.
PURPOSE: The American College of Cardiology/American Heart Association (ACC/AHA) guidelines are based on studies with a limited number of Asian subjects; therefore, they are difficult to apply to Asian patients, including Korean patients. MATERIALS AND METHODS: Data were extracted from the clinical data warehouse system of Seoul St. Mary's hospital (January 2010 - December 2012) to determine the percent change in low-density lipoprotein cholesterol (LDL-C) levels at an average 3 and 6 months from baseline. Statins with statistically similar lowering effects were placed in one group (group A, B, or C). The proportions of patients who achieved LDL-C < 100 mg/dL were compared between baseline LDL-C levels: low (< 130 mg/dL), medium (130 - 160 mg/dL), and high (> 160 mg/dL). RESULTS: The majority of the 9 statins of various doses (2,349 patients) were effective at 3 months, with additional, smaller decreases at 6 months. The LDL-C lowering effect of group A (atorvastatin (20 mg), rosuvastatin (10 mg)) was ~ 45%; that of group B (atorvastatin (10 mg), pitavastatin (2 mg), pravastatin (40 mg), simvastatin (20 mg)) was 35 - 37%. groups A and B contained only moderate-intensity statins (ACC/AHA guidelines). With baseline LDL-C ≥ 130 mg/dL, greater proportions of patients achieved LDL-C < 100 mg with atorvastatin (20 mg) and rosuvastatin (10 mg). CONCLUSION: Because of the demonstrated LDL-C lowering effects and target achievement rates, the ACC/AHA guidelines might not apply to Korean patients. Korean treatment guidelines should consider statins with relatively low potency. Additional studies regarding appropriate statin doses should be conducted with Asian populations.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2016) conducted a cohort in Dyslipidemia (n=2,349). Group A statins (atorvastatin 20 mg, rosuvastatin 10 mg) vs. Group B statins (atorvastatin 10 mg, pitavastatin 2 mg, pravastatin 40 mg, simvastatin 20 mg) was evaluated on Percent change in low-density lipoprotein cholesterol (LDL-C) levels at 3 months. Moderate-intensity statins reduced LDL-C by ~45% at 3 months in Korean patients, suggesting lower doses may be highly effective in Asian populations.
Synapse has enriched 10 related papers. Consider them for comparative context: